Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.01 USD
Change Today +0.01 / 0.50%
Volume 45.5K
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

vermillion inc (VRML) Key Developments

Vermillion, Inc. Announces Positive Top-Line Results Regarding OVA2 Development and Clinical Validation

Vermillion, Inc. announced publication of two abstracts reporting initial positive top-line results regarding the development and validation of OVA2, Vermillions second-generation OVA1 ovarian cancer triage test. The abstracts represent the first publication of data from OVA2 development, and underpin Vermillions submission of OVA2 for 510(k) clearance to the FDA. The data show significant improvement in OVA2 specificity compared to OVA1, while maintaining strong sensitivity (92% for OVA1 in a 2013 pivotal study). Vermillions goal is to launch OVA2 by the third quarter of this year, dependent on successful and timely FDA clearance. Validation of a second-generation MIA (MIA2G) for triage of adnexal masses reported on the validation of OVA2 (under a generic name, MIA2G). Across all subjects, 33% fewer benign positives were seen with OVA2 compared with OVA1. The validation study showed statistically significant improvement in specificity as a risk stratification test (OVA2 alone), with no significant reduction of sensitivity or negative predictive value (NPV). Sensitivity and NPV were not reported in the abstract, but will be shown in the poster itself as compared to OVA1. The large validation cohort also showed statistically significant improvement in positive predictive value (PPV), as well as a 12% improvement in overall test accuracy, defined as (true positives + true negatives) ÷ (N) compared to OVA1. Derivation of a second generation multivariate index assay (MIA2G) to improve specificity in pre-surgical evaluation of adnexal masses for risk of ovarian cancer. As a result of the development work, OVA2 will measure a woman’s risk of cancer using a 0 to 10 scale, as with the OVA1 test. OVA2, however, has a single cutoff; less than 5.0 for low risk and greater than or equal to 5.0 for high risk. This design greatly simplifies testing procedures and interpretation.

Vermillion, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Vermillion, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $951,000 against $305,000 a year ago. Loss from operations was $4,262,000 against $3,995,000 a year ago. Net loss was $4,137,000 against $3,987,000 a year ago. Basic and diluted net loss per share was $0.10 against $0.11 a year ago. The company has no remaining debt as of March 31, 2015. The company utilized $4.5 million in cash in operations in the first quarter as well as the $1.1 million for the repayment of short-term debt.

Vermillion, Inc., Annual General Meeting, Jun 18, 2015

Vermillion, Inc., Annual General Meeting, Jun 18, 2015., at 08:00 Eastern Daylight. Location: DoubleTree by Hilton Tarrytown at 455 South Broadway. Agenda: To elect as directors the eight nominees named in the proxy statement and recommended by the board of directors to serve for a one-year term expiring at the 2016 annual meeting of stockholders and until their successors are elected and qualified; to hold an advisory vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement; to approve the second amendment of the Vermillion, Inc. Amended and Restated 2010 Stock Incentive Plan; to ratify the selection of BDO USA, LLP as the company’s independent registered public accounting firm for the year ending December 31, 2015; to transact such other business as properly may be brought before the Annual Meeting or any adjournment or postponement thereof.

Vermillion, Inc. to Report Q1, 2015 Results on May 11, 2015

Vermillion, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 11, 2015

Vermillion, Inc., Q1 2015 Earnings Call, May 11, 2015

Vermillion, Inc., Q1 2015 Earnings Call, May 11, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRML:US $2.01 USD +0.01

VRML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arrayit Corp $0.0028 USD -0.0001
Imperial Innovations Group PLC 485.00 GBp 0.00
Jeol Ltd ¥520.00 JPY 0.00
MDxHealth €4.80 EUR 0.00
Miraculins Inc C$0.07 CAD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VRML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.2x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERMILLION INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at